Gemcitabine Prevents TCC Relapse
Adda Bounedjar, MD, and his colleagues at Centre Pierre et Marie Curie in
The 60 patients received a total of 720 instillations. After a follow-up period of 30-48 months, 53 patients (88.3%) had a persistent complete remission following TUR, five (8.3%) had a superficial relapse of TCC, and two (3.3%) had progressive disease at 18 and 27 months, the investigators reported here at the American Society of Clinical Oncology annual meeting.
Hematologic and non-hematologic toxicities were grade 1, and included anemia (6.8% of patients), leukopenia (4.5%), thrombocytopenia (0.4%), asthenia (2.9% of patients), nausea and vomiting (1.8%), and hot flashes (2%).